Home / Stocks / Strides Pharma Sci Ltd
STAR

Strides Pharma Sci Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹979.1

Change

+21.0 (2.19%)

Open

₹958.1

Prev. Close

₹958.1

Day High

₹984.9

Day Low

₹952.3

Volume Analysis

Traded

388,914

Delivered

198,064

Delivery %

50.93%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (20.0%)
  • •Promoter holding is rising

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,024.5 ₹1,004.7 ₹991.9 ₹972.1 ₹959.3 ₹939.5 ₹926.7
Fibonacci ₹1,004.7 ₹992.25 ₹984.55 ₹972.1 ₹959.65 ₹951.95 ₹939.5
Camarilla ₹988.07 ₹985.08 ₹982.09 ₹972.1 ₹976.11 ₹973.12 ₹970.14

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+7.43%

1 Week

-2.99%

1 Month

-4.51%

3 Months

-0.72%

6 Months

-15.1%

1 Year

+6.03%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹709.71

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

17.4%

Net margin 12.22% × asset turnover 0.65x × equity multiplier 2.19x

Company Overview

Sector

Healthcare

Market Cap

₹9,353 Cr

P/E (TTM)

16.2

ROE

20.0%

Book Value

₹371.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Strides Pharma Sci Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (85/100), while Momentum (50/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (20.0%); promoter holding is rising. FII holding has been rising.

TopFund Score — Fundamentals Quality

65/100 — Good

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

85

Growth

54

Valuation

52

Cash Flow

53

Corporate Governance

61

Momentum

50

Institutional Ownership

64

Business Quality

76

Risk & Volatility

64

Liquidity

81

From Screener.in

  • +Company has delivered good profit growth of 20.1% CAGR over last 5 years
  • +Company has a good return on equity (ROE) track record: 3 Years ROE 57.0%
  • −Stock is trading at 2.74 times its book value
  • −The company has delivered a poor sales growth of 7.94% over past five years.
  • −Promoter holding is low: 29.0%
  • −Promoters have pledged 33.8% of their holding.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Transcript of Earnings Call pertaining of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026

Newspaper Advertisement - Unaudited Financial Results for the quarter and half year ended September 30, 2026

Audio recording of earnings call for Q2 and H1 FY2026 results available on website.

Allotment of Equity shares pursuant to exercise of Stock Options.

Board appointed Biren Gabhawala as Non-Executive Independent Director from November 1, 2026 for five years.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 999 1,006 1,044 1,054 1,167 1,154 1,190 1,120 1,221 1,195 1,323 1,265 1,430
Expenses + 889 876 874 866 983 943 973 902 990 959 1,084 1,037 1,179
Operating Profit 111 129 169 188 184 210 218 218 231 236 240 228 251
OPM % 11.0% 13.0% 16.0% 18.0% 16.0% 18.0% 18.0% 19.0% 19.0% 20.0% 18.0% 18.0% 18.0%
Other Income + -129 60 -27 3,299 25 4 -12 0 18 104 3 68 3
Interest 79 70 71 73 74 52 50 47 46 43 42 41 47
Depreciation 60 49 48 47 48 48 49 49 50 51 53 56 57
Profit before tax -157 70 23 3,369 86 114 106 122 153 245 148 200 150
Tax % -5.0% 23.0% 55.0% 1.0% 16.0% 21.0% 20.0% 13.0% 14.0% 15.0% 13.0% 17.0% 11.0%
Net Profit + -149 54 10 3,350 72 90 86 106 132 208 129 165 134
EPS in Rs -15 5 2 365 8 10 9 11 14 22 14 17 14
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 11 16 6 13 17 15 14 6 5 4 11 13 17

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 1,196 2,861 2,755 2,845 2,178 2,752 3,316 3,070 3,688 3,890 4,565 4,859 5,213
Expenses + 967 2,486 2,228 2,448 1,982 2,338 2,779 3,201 3,544 3,362 3,763 3,933 4,258
Operating Profit 229 374 527 398 197 414 537 -131 145 528 803 925 955
OPM % 19.0% 13.0% 19.0% 14.0% 9.0% 15.0% 16.0% -4.3% 3.9% 14.0% 18.0% 19.0% 18.0%
Other Income + 874 63 291 643 303 -43 109 -112 92 -100 3,313 124 178
Interest 47 168 183 196 79 156 150 177 261 280 249 179 172
Depreciation 64 131 126 154 117 174 206 233 243 214 192 202 217
Profit before tax 992 137 509 690 303 42 289 -653 -268 -65 3,675 669 744
Tax % 15.0% 31.0% 12.0% 1.0% -9.0% 27.0% 11.0% -27.0% -21.0% 45.0% 2.0% 14.0% —
Net Profit + 844 95 446 684 330 31 258 -474 -212 -94 3,598 575 637
EPS in Rs 142 12 45 74 36 4 30 -51 -22 -8 390 60 67
Dividend Payout % 76.0% 41.0% 10.0% 3.0% 8.0% 345.0% 8.0% 0.0% -7.0% -33.0% 1.0% 8.0% —
Sales growth -11 139 -4 3 -23 26 20 -7 20 5 17 6 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 1,085 2,569 2,659 2,374 2,559 2,438 2,687 2,269 2,122 2,034 2,460 3,015 3,324
Borrowings + 892 3,542 3,700 2,520 3,221 2,235 2,348 3,025 3,030 2,517 1,880 1,758 1,905
Other Liabilities + 438 1,211 1,598 1,601 1,937 1,369 1,844 1,556 1,352 1,157 1,498 1,941 2,167
Total Liabilities 2,475 7,410 8,046 6,585 7,807 6,131 6,969 6,940 6,594 5,799 5,929 6,807 7,489
Fixed Assets + 701 2,679 2,980 2,977 3,648 2,099 2,219 2,347 2,311 1,865 1,899 2,101 2,406
CWIP 171 815 780 620 453 413 447 291 151 162 207 447 226
Investments 630 1,341 1,525 588 702 549 697 540 490 303 409 291 346
Other Assets + 972 2,576 2,762 2,400 3,005 3,070 3,605 3,762 3,642 3,470 3,414 3,967 4,510
Total Assets 2,475 7,410 8,046 6,585 7,807 6,131 6,969 6,940 6,594 5,799 5,929 6,807 7,489
Equity Capital 60 89 89 90 90 90 90 90 90 92 92 92 92

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 83 73 288 187 60 205 481 -258 44 701 684 703
Cash from Investing Activity + 50 -2,205 -1,222 570 -145 1,321 -522 -119 302 -150 -90 -173
Cash from Financing Activity + -421 2,944 338 -1,016 194 -1,709 -16 421 -214 -693 -643 -453
Net Cash Flow -288 812 -596 -259 110 -184 -56 45 133 -142 -48 76
Free Cash Flow -157 -293 -386 -212 -256 58 188 -326 -43 672 505 291
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 61 40 66 61 59 60 60 199 -30 128 77 84

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 27.39% → 29.0%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 33.75% 31.52% 28.87% 25.83% 27.78% 29.65% 30.38% 30.62% 29.59% 28.96% 28.28% 27.52%
Promoters 27.39% 25.88% 25.86% 25.84% 26.82% 28.3% 28.3% 27.86% 27.86% 27.91% 27.91% 29.0%
Government 0.39% 0.39% 0.39% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
FII 19.45% 24.57% 26.71% 30.08% 28.48% 28.32% 28.02% 28.51% 29.52% 28.68% 28.4% 27.98%
DII 19.02% 17.66% 18.17% 18.24% 16.92% 13.72% 13.3% 12.98% 13.02% 14.44% 15.42% 15.51%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Strides Pharma Sci Ltd (this stock) 9,353 16.2 2.74 20.0%
Paras Healthcare Limited 9,284 129.0 — 13.0%
Aarti Pharmalabs Limited 9,212 35.4 4.08 8.59%
Jupiter Life Line Hosp L 9,507 50.0 5.84 13.1%
Blue Jet Healthcare Ltd 9,989 70.9 — 52.1%
Healthcare Glob. Ent. Ltd 8,562 216.0 6.36 2.54%
Yatharth Hosp & Tra C S L 10,222 53.6 5.44 10.2%

Which Mutual Funds Hold Strides Pharma Sci Ltd?

Frequently Asked Questions about Strides Pharma Sci Ltd

Community Sentiment

What are other investors saying about Strides Pharma Sci Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.